Not all DCIS patients will benefit from the addition of radiation therapy to their treatment. Genomic Health's Oncotype DX Breast Cancer Assay for DCIS patients provides a DCIS score from which breast cancer doctors and their patients can determine the appropriate personalized treatment plan.
Genomic Health's Dr. Rick Baehner, Senior Director of Pathology, reviews the various treatment options for those diagnosed with DCIS breast cancer. The Oncotype DX DCIS Breast Cancer Assay and DCIS Score only apply to those breast cancer patients who have a lumpectomy.
In this video, Dr. Jay K. Harness talks about the seriousness of DCIS breast cancer. Click Here & Get The 15 Breast Cancer Questions To Ask Your Doctor http://www.breastcanceranswers.com/what-breast-cancer-questions-to-ask/# Breast Cancer Answers is a social media show where viewers submit a question and get the answer from an expert. Submit your question now at, http://www.breastcanceranswers.com/ask. This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk. If you have any concerns about your health, please consult with a physician.
What is the likelihood of DCIS breast cancer coming back after treatment? Dr. Rick Baehner, Senior Director of Pathology at Genomic Health, talks about what DCIS breast cancer patients can expect in terms of percentages.
Patients diagnosed with DCIS breast cancer can obtain an Oncotype DX DCIS Score, which is covered by Medicare, but reimbursement for private payers can vary. Genomic Health Senior Director of Pathology Dr. Rick Baehner explains that Genomic Health will work with DCIS breast cancer patients and their insurance companies to arrange coverage.